Previous 10 | Next 10 |
Medicine company Aziyo Biologics' (NASDAQ:AZYO) co-founder, C. Randal (Randy) Mills, is appointed interim president and CEO. Mills succeeds Ronald Lloyd, who will remain with the company through Q3-end. Additionally, Co-founder Kevin Rakin is appointed executive chairman. ...
Aziyo Biologics (NASDAQ:AZYO) stated Tuesday that co-founder C. Randal (Randy) Mills has been appointed as company's interim president and chief executive officer, succeeding Ronald Lloyd. The company told Lloyd will step down from the roles but with remain with it through the end ...
SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-fou...
Aziyo Biologics, Inc. (AZYO) Q1 2022 Earnings Conference Call May 9, 2022, 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Financial Officer Leigh Salvo – Investor Relations, Gilmartin Group, LLC Conference Cal...
Aziyo Biologics press release (NASDAQ:AZYO): Q1 GAAP EPS of -$0.60. Revenue of $11.5M (-10.9% Y/Y). For further details see: Aziyo Biologics GAAP EPS of -$0.60, revenue of $11.5M
SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today provided a business upd...
SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it pla...
SILVER SPRING, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that the Co...
Silver Spring, Md.-based Aziyo Biologics (NASDAQ:AZYO) filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its CanGaroo RM Antibacterial Envelope product, a biomaterial envelope for use with cardiac implantable electronic devices ((CIEDs)). CIEDs...
SILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo ® RM Antibacterial Envelope, its next-generation biomateria...
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...